{"altmetric_id":3591652,"counts":{"readers":{"mendeley":3,"citeulike":0,"connotea":0},"total":{"posts_count":1},"wikipedia":{"unique_users_count":1,"unique_users":["en:22570393"],"posts_count":1}},"citation":{"abstract":"AstraZeneca (formerly Astra) is developing robalzotan, a 5-HT1A antagonist, for the potential treatment of depression and anxiety. The compound has entered phase II trials, and NDA and MAA filings are expected after 2003 [352095,377656]. In August 2000, Lehman Brothers predicted that the compound had a 20% probability of reaching the market, with a predicted launch date of 2005 [384880].","abstract_source":"pubmed","altmetric_jid":"4f6fa6143cf058f610007072","authors":["H A Mucke"],"first_seen_on":"2015-02-13T13:26:05+00:00","handles":[],"isbns":[],"issns":["1472-4472"],"issue":"2","journal":"Current Opinion in Investigational Drugs","last_mentioned_on":1240731416,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11249580"],"pmid":"11249580","pubdate":"2000-10-01T00:00:00+00:00","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Life Sciences","Pharmacology, Toxicology and Pharmaceutics"],"subjects":["drugtherapy"],"title":"Robalzotan AstraZeneca.","type":"article","volume":"1","mendeley_url":"http:\/\/www.mendeley.com\/research\/robalzotan-astrazeneca"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":3622349,"mean":4.9309966560279,"rank":815997,"this_scored_higher_than_pct":63,"this_scored_higher_than":2282743,"rank_type":"exact","sample_size":3622349,"percentile":63},"similar_age_3m":{"total_number_of_other_articles":94061,"mean":7.430428390691,"rank":23947,"this_scored_higher_than_pct":73,"this_scored_higher_than":69035,"rank_type":"exact","sample_size":94061,"percentile":73},"this_journal":{"total_number_of_other_articles":114,"mean":2.7695221238938,"rank":15,"this_scored_higher_than_pct":26,"this_scored_higher_than":30,"rank_type":"exact","sample_size":114,"percentile":26},"similar_age_this_journal_3m":{"total_number_of_other_articles":1,"mean":0,"rank":1,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":1,"percentile":1}}},"demographics":{"users":{"mendeley":{"by_status":{"Student  > Ph. D. Student":1,"Student  > Master":1,"Student  > Bachelor":1},"by_discipline":{"Medicine and Dentistry":3}}},"geo":{"mendeley":{"NL":1}}},"posts":{"wikipedia":[{"title":"Robalzotan","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=286189803#altmetric_citation_2","license":"public","citation_ids":[3591652],"posted_on":"2009-04-26T07:36:56+00:00","summary":"Robalzotan (NAD-299, AZD-7371) is a selective antagonist at the 5-HT1A receptor. It was shown to completely reverse the autoreceptor-mediated inhibition of serotonin release induced by the administration of selective serotonin reuptake inhibitors like cita","page_url":"http:\/\/en.wikipedia.org\/?curid=22570393","wiki_lang":"en","author":{"name":"Vanished 45kd09la13","url":"http:\/\/en.wikipedia.org\/wiki\/User:Vanished 45kd09la13"}}]}}